Literature DB >> 1775968

Theory and application of early systemic therapy.

D T Harris1, M J Mastrangelo.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1775968

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  7 in total

1.  Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.

Authors:  D G Power; D H Ilson
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

2.  Early post-operative 5-fluorouracil does not affect the healing of experimental intestinal anastomoses.

Authors:  J W de Waard; T Wobbes; T Hendriks
Journal:  Int J Colorectal Dis       Date:  1993-09       Impact factor: 2.571

3.  Is early post-operative treatment with 5-fluorouracil possible without affecting anastomotic strength in the intestine?

Authors:  B M van der Kolk; B M de Man; T Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

Authors:  H R Haak; J Hermans; C J van de Velde; E G Lentjes; B M Goslings; G J Fleuren; H M Krans
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

5.  Inhibition of basal and TGF beta-induced fibroblast collagen synthesis by antineoplastic agents. Implications for wound healing.

Authors:  T Hendricks; M F Martens; C M Huyben; T Wobbes
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

6.  The effects of 5-fluorouracil and interferon-alpha on early healing of experimental intestinal anastomoses.

Authors:  J W de Waard; T Wobbes; B M de Man; C J van der Linden; T Hendriks
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

7.  Post-operative levamisole may compromise early healing of experimental intestinal anastomoses.

Authors:  J W de Waard; T Wobbes; B M de Man; C J van der Linden; T Hendriks
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.